A2780 Cell Line Product
[…] drug resistant cell line variants: a cisplatin resistant cell line – A2780 cis (catalogue no. 152708) and the adriamycin resistant cell line – A2780 ADR (catalogue no. 152707).  _x000D_ _x000D_ […]
Showing results for pea1 pea2 peo 152708 152706 152707 152708 155270 155270 152708 152706 152707 peo 152708 152706 152707 152708 155270 155270 152708 152706 152707 152708 152706 152707 152708 155270 155270 152708 152706 152707
[…] drug resistant cell line variants: a cisplatin resistant cell line – A2780 cis (catalogue no. 152708) and the adriamycin resistant cell line – A2780 ADR (catalogue no. 152707).  _x000D_ _x000D_ […]
The PEO4 cell line is one of nine from the PE ovarian adenocarcinoma panel (derived from 4 patients at varying stages of ovarian cancer, isolated from various malignant sites, and […]
The PEO1 Cell Line is one of nine lines from the PE ovarian adenocarcinoma panel. These lines were derived from 4 patients at varying stages of ovarian cancer and were […]
[…] has been developed by exposure of adriamycin to the parent A2780 cell line (catalogue no. 152706). Adriamycin (doxorubicin) is frequently used as a therapeutic agent for cancer, by interfering with […]
PEA2 cell line: One of nine from the PE ovarian adenocarcinoma panel. Adherent cell collected on relapse after treatment with cisplatin and prednimustine.
PEO6 is an adherent cell line derived from a malignant effusion from the peritoneal ascites of a patient with a poorly differentiated serous adenocarcinoma.
PEO16 cell line: Collected after radiotherapy. Part of the PE ovarian adenocarcinoma panel (derived from 4 patients at varying stages of ovarian cancer).
PEA1 is an adherent cell line derived from a malignant effusion from the pleural cavity of a patient with a poorly differentiated adenocarcinoma.
PEO23 was collected on relapse after cisplatin and chlorambucil treatment. PEO23 exhibits poor growth in semi-solid medium (agar). PEO23 is from the same patient asTO14 cell lines.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.